New Hope for Blood Cancer Patients Who Can’t Tolerate Chemo -"Venetoclax by AbbVie"

US pharmaceutical giant AbbVie has made a significant stride in India’s fight against blood cancers with the launch of Venetoclax, an innovative oral therapy targeting Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL). This launch marks AbbVie’s formal entry into the Indian oncology market, underscoring the company’s commitment to expanding cancer care options in the country.

Venetoclax is a first-in-class BCL-2 inhibitor that selectively attacks cancer cells in the blood and bone marrow. Its novel mechanism offers renewed hope, especially for patients who are elderly or have comorbidities that make intensive chemotherapy unfeasible. Unlike conventional intravenous treatments, Venetoclax’s oral dosing regimen allows for more personalized and convenient therapy, a crucial advantage in India where delayed diagnosis and limited access to advanced treatments remain major challenges.

According to data from the All India Institute of Medical Sciences (AIIMS), Delhi, AML affects approximately 2.5 individuals per 100,000 population in India. Although relatively rare, AML is an aggressive blood cancer with limited treatment options, particularly for older patients or those unable to tolerate harsh chemotherapy regimens. Venetoclax’s introduction addresses this critical gap by providing an effective alternative that can improve life expectancy and quality of life.

Previously, AbbVie’s oncology footprint in India was limited to Imbruvica, marketed by Johnson & Johnson. With Venetoclax, AbbVie now directly controls pricing and distribution, enabling better accessibility and support for patients. The company has priced Venetoclax at a maximum retail price of Rs 15,900 per bottle, covering about 12 days of treatment, roughly translating to Rs 30,000 per month. To further ease patient access, AbbVie plans to implement a patient assistance program aimed at financially vulnerable individuals.

The drug’s launch follows regulatory approval from India’s Central Drugs Standard Control Organization and aligns with government initiatives to decentralize cancer care infrastructure beyond major metropolitan centers into tier-2 and tier-3 cities. AbbVie intends to collaborate closely with local hospitals to train healthcare providers on Venetoclax administration and establish robust supply chains to reach smaller and underserved healthcare facilities.

Dr. Rahul Rathod, AbbVie’s Medical Director, highlighted Venetoclax as a promising option for patients ineligible for intensive chemotherapy, emphasizing its potential to extend survival and allow patients to spend more meaningful time with their families. Suresh Pattathil, Managing Director & General Manager of AbbVie India, described the company’s oncology debut as a strong commitment to transforming cancer treatment in India and addressing unmet patient needs.

In summary, AbbVie’s launch of Venetoclax represents a landmark advancement in India’s oncology landscape. By introducing this targeted oral therapy, AbbVie not only broadens treatment choices for blood cancer patients—particularly those with limited options due to age or health conditions—but also supports the broader goal of making cancer care more accessible and personalized across the country. This strategic move is poised to reshape blood cancer management in India, offering renewed hope to patients and healthcare providers alike.

 How does Venetoclax's oral dosing regimen benefit patients?

.

Venetoclax’s oral dosing regimen offers several important benefits for patients, particularly those with blood cancers like chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML):

1. Convenience and Quality of Life: Being an oral medication, Venetoclax allows patients to take their treatment at home, reducing the need for frequent hospital visits or intravenous infusions. This convenience can significantly improve patients’ quality of life and adherence to therapy.

   
   

2. Personalized and Controlled Dose Ramp-Up: Venetoclax dosing begins with a carefully managed "ramp-up" phase, where the dose is gradually increased over several weeks (typically five weeks for CLL) from a low starting dose to the target dose. This slow escalation helps minimize the risk of tumor lysis syndrome (TLS), a potentially serious complication caused by rapid cancer cell death. The ramp-up dosing is tailored to the patient’s condition and concomitant medications, ensuring safer administration.

   
   

3. Fixed-Duration Treatment Option: For some regimens, Venetoclax offers a fixed duration of therapy, which can provide patients with a treatment-free period afterward. This break from daily medication can reduce the psychological burden of continuous cancer treatment and improve overall well-being.

   
   

4. Flexibility in Combination Therapies: Venetoclax’s oral form facilitates its use in combination with other agents (e.g., azacitidine, decitabine) with coordinated dosing schedules. This flexibility allows oncologists to design effective, lower-intensity regimens suitable for older or unfit patients who cannot tolerate intensive chemotherapy.

   
   

5. Reduced Hospitalization Needs: The oral regimen and outpatient ramp-up dosing reduce the necessity for prolonged hospital stays, making treatment more accessible, especially in settings where inpatient care is limited.

 Sources : INDIAMED TODAY